Cannabinoids and pain relief

References

• Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem. Pharmacol. 52, 819–827 (1996).
   PubMed Web of Science ®Google Scholar
• Twitchell W Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. j Neurophysiol 78, 43–50 (1997).
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Pharmacology of cannabinoid CBI and CB2 receptors. Pharmacol. Then 74, 129–180 (1997).
   Google Scholar
• •A useful pharmacological outline.
   Google Scholar
• Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Aiumscience 83, 393–411 (1998).
   Google Scholar
• •Demonstrates a relative lack of cannabinoid receptors in the brain stem, in contrast with opioid receptors.
   Google Scholar
• Hohmannn AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822, 17–25 (1999).
   Google Scholar
• Di Marzo V, Breivogel CS, Tao Q et al Levels, metabolism and pharmacological activity in CBI cannabinoid receptor knockout mice. .1. Neumchem. 75, 2343–2444 (2000).
   Google Scholar
• Felder CC, Joyce KE, Briley EM et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CBI and CB2 receptors. Mot. Pharmacol 48, 443–450 (1995).
   Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L et al Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol 50, 83–90 (1995).
   Google Scholar
• Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptors (CB2): identification of cannabinoid receptor subtype selective ligands. I Pharmacol Exp. Then 278, 989–999 (1996).
   Google Scholar
• Rinaldi-Carmona M, Barth F, Milan J et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. I Pharmacol Exp. Then 284, 644–650 (1998).
   Google Scholar
• Ross RA, Brockie HC, Stevenson LA et al. Agonist-inverse agonist characterization at CBI and CB2 receptors of L759633, L759656 and AM630. BE I Pharmacol 126, 665–672 (1999).
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Gibson TM, Stevenson LA et al 0-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. BE I Pharmacol 129, 1577–1584 (2000).
   PubMed Web of Science ®Google Scholar
• •This paper describes a water-soluble cannabinoid, 0–1057, that has significant potential for drug development and delivery (e.g., it. route).
   Google Scholar
• Pertwee RG. Cannabinoid receptor ligands: clinical and neuropharmacological considerations relevant to future drug discovery and development. Exp. Opin. Invest. Drugs 9, 1–19 (2000).
   Web of Science ®Google Scholar
• Zygmunt PM, Petersson J, Andersson DA et al Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452–457 (1999).
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Fride E, Di Marzo V Endocannabinoids. Eun I Pharmacol 359, 1–18 (1998).
   PubMed Web of Science ®Google Scholar
• Lambert DM, DiMarzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimetic? CUI7: Merl Chem. 6, 757–773 (1999).
   Google Scholar
• Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394, 227–281 (1998).
   PubMed Web of Science ®Google Scholar
• British Medical Association. Therapeutic uses of Cannabis. Harwood Publishers UK (1997).
   Google Scholar
• •A book written by the British Medical Association Scientific Committee focussing on human uses of cannabis.
   Google Scholar
• Joy JE, Watson SJ, Jr., Benson JA. Marijuana and medicine: Assessing the Science Base. Washington DC: National Academy Press (1999).
   Google Scholar
• •• A comprehensive scientific report from the National Academy of Sciences (USA) available at http://bob.nap.edu/html-marimed/notice.html.
   Google Scholar
• House of Lords. Cannabis: the Scientific and Medical Evidence. Ninth Report from the Select Committee on Science and Technology. London: The Stationery Office, (1998). A detailed report following evidence given by scientific and governmental bodies within and outside the UK
   Google Scholar
• Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pre-treatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug-Utah. Display. 23, 825–831 (1995).
   Google Scholar
• Zuardi AW, Morals SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. j Clin. Psych. 56, 485–486 (1995).
   Google Scholar
• Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobial Dis. 5, 447–461 (1998).
   PubMed Web of Science ®Google Scholar
• Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K The neurobiology of cannabinoid antinociception. Life Sci. 65, 665–673 (1999).
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats:evidence supporting periaqueductal gray involvement. J. Pharmacol Exp. Ther. 276, 585–593 (1996).
   Google Scholar
• Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail flick reflex after microinjection into the rostral ventromedial medulla. AilllESCE Lett. 242, 33–36 (1998).
   Google Scholar
• Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity on the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. Neurosci. 16, 6601–6611 (1996).
   Web of Science ®Google Scholar
• Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 395, 381–383 (1998).
   PubMed Web of Science ®Google Scholar
• Vaughan CW, McGregor IS, Christie MJ. Cannabinoid receptor activation inhibits its GABAergic neurotransmission in rostral ventromedulla neurones in vitro. BE j Pharmacol 127, 935–940 (1999).
   Google Scholar
• Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. 848, 183–190 (1999).
   PubMed Web of Science ®Google Scholar
• Richardson JD, Aanonsen L, Hargreaves KL. 5R141716A, a cannabinoid receptor anagonist, produces hyperalgesia in untreated mice. Eur. Pharmacol 319, R3-4 (1997).
   Google Scholar
• Richardson JD, Aanonsen L, Hargreaves KL. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. Neumsci. 18, 451–457 (1998).
   Google Scholar
• Strangman NM, Patrick SL, Hohman AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 813, 323–328 (1998).
   Google Scholar
• Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur. j Pharmacol 345, 145–153 (1998).
   Google Scholar
• Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neural 38, 44–48 (1997).
   Google Scholar
• Li J, Daughters RS, Bullis C et al The cannabinoid receptor agonist WIN 55212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain 81, 25–33 (1999)
   PubMed Web of Science ®Google Scholar
• Strangman NM, Walker JM. Cannabinoid WIN 55212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. I Neurophysiol 82, 472–477 (1999).
   PubMed Web of Science ®Google Scholar
• Tsou K, Lowitz KA, Hohman AG et al Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neurosci 70, 791–798 (1996).
   PubMed Web of Science ®Google Scholar
• Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76, 189–199 (1998).
   PubMed Web of Science ®Google Scholar
• Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221, 157–160 (1997).
   Google Scholar
• Hohman AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal horn ganglia: a double-label in situ hydridization study. Neurosci 90, 923–931 (1999).
   Web of Science ®Google Scholar
• Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation Oa interaction with peripheral CB1 receptors. Pain 75, 111–119 (1998).
   Google Scholar
• Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon A. N- (2-hydroxyethyl) hexadecanamide is orally-active in reducing oedema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. Pharmacol 3000, 227–236 (1996).
   Google Scholar
• Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CBI receptors. Eur. Pharmacol 307, 331–338 (1996).
   Google Scholar
• Holdcroft A, Smith M, Jacklin A et al. Pain relief with oral cannabinoids in familial Mediterranean Fever. Anaesthesia 52, 483–488 (1997).
   PubMed Web of Science ®Google Scholar
• •The only clinical trial of cannabis plant extract in acute on chronic pain.
   Google Scholar
• Holdcroft A, Smith M, Smith B, Hodgson H, Evans FJ. Clinical trial experience with cannabinoids. Pharm. Li. 3, 546–550 (1997).
   Google Scholar
• Notcutt W Personal Communication (2001).
   Google Scholar
• Hall W, Solowij N, Adverse effects of cannabis. Lancet352, 1611–1616 (1998).
   PubMed Web of Science ®Google Scholar
• Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 60, 1303–1314 (2000).
   PubMed Web of Science ®Google Scholar
• Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sciences 56, 2119–2126 (1995).
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration. Rescheduling of synthetic dronabinol from Schedule II to Schedule III. .&cletal Register 53, 59751–59753 (1998).
   Google Scholar
• British National Formulary, British Medical Association and the Royal Pharmaceutical Society of Great Britain, 202–203 (2000).
   Google Scholar
• Walker LA, Harland EC, Best AM, Elsohly MA. 49 THC hemisuccinate in suppository form as an alternative to oral and smoked THC. In Marihuana and Medicine Nahas GG, Sutin KM, Harvey DJ, Agurell S (Eds), Human Press, Totowa, NJ, USA, 123–135 (1999).
   Google Scholar
• Fields HL, Meng ID. Watching the pot boil. Nature Medicine4, 1008–1009 (1998).
   PubMed Web of Science ®Google Scholar
• •A futuristic view of cannabinoids.
   Google Scholar
• Barth E Cannabinoid receptor agonists and antagonists. Exp. Opin. Ther. Patents 8, 301–313 (1998)
   Google Scholar
• Dajani EZ, Larsen KR, Taylor J et al. -Dimethylheptyl-delta-8-tetrahydrocannabino1-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. I Pharmacol Exp. Ther. 291, 31–38 (1999).
   Google Scholar
• Pop E. Dexanabinol Pharmos. CU17: Opin. Investig Drugs1,494–503 (2000).
   Google Scholar
• Pertwee RC. Cannabinoid receptors and pain. Prog. Neurobiol 63,569–611 (2001).
   PubMed Web of Science ®Google Scholar
• ••A timely review of the pharmacology ofcannabinoids and pain.
   Google Scholar